2型糖尿病合并心房颤动的危险因素分析(4)
[14] Vítek L，Jirsa M，Brodanová M，et al. Gilbert syndrome and ischemic heart disease：a protective effect of elevated bilirubin levels [J]. Atherosclerosis，2002，160(2)：449-456.
[15] Dekker D，Dorresteijn MJ，Pijnenburg M，et al. The Bilirubin-Increasing Drug Atazanavir Improves Endothelial Function in Patients With Type 2 Diabetes Mellitus [J]. Arterioscler Thromb Vasc Biol，2011，31(2)：458-463.
[16] Iguchi Y，Kimura K，Aoki J，et al. Prevalence of atrial fibrillation in community-dwelling Japanese aged 40 years or older in Japan：analysis of 41，436 non-employee residents in Kurashiki-city [J]. Circ J，2008，72(6)：909-913.
[17] Watanabe H， Aizawa Y. Letter by Watanabe and Aizawa regarding article，"Blood lipid levels，lipid-lowering medications，and the incidence of atrial fibrillation：the Atherosclerosis Risk in Communities (ARIC) Study" [J]. Circ Arrhythm Electrophysiol，2012，5(1)：155.
[18] Watanabe H，Tanabe N，Yagihara N，et al. Association between lipid profile and risk of atrial fibrillation [J]. Circ J，2011，75(12)：2767-2774.
[19] Díaz-Peromingo JA，Albán-Salgado A，García-Suárez F，et al. Lipoprotein(a) and lipid profile in patients with atrial fibrillation [J]. Med Sci Monit，2006，12(3)：CR122-CR125.
[20] Suzuki S. “Cholesterol paradox”in atrial fibrillation [J]. Circ J，2011，75(12)：2749-2750.
(收稿日期：2018-09-12 本文編辑：封 华), 百拇医药(邱娜 凌宏威 周冬梅)
[15] Dekker D，Dorresteijn MJ，Pijnenburg M，et al. The Bilirubin-Increasing Drug Atazanavir Improves Endothelial Function in Patients With Type 2 Diabetes Mellitus [J]. Arterioscler Thromb Vasc Biol，2011，31(2)：458-463.
[16] Iguchi Y，Kimura K，Aoki J，et al. Prevalence of atrial fibrillation in community-dwelling Japanese aged 40 years or older in Japan：analysis of 41，436 non-employee residents in Kurashiki-city [J]. Circ J，2008，72(6)：909-913.
[17] Watanabe H， Aizawa Y. Letter by Watanabe and Aizawa regarding article，"Blood lipid levels，lipid-lowering medications，and the incidence of atrial fibrillation：the Atherosclerosis Risk in Communities (ARIC) Study" [J]. Circ Arrhythm Electrophysiol，2012，5(1)：155.
[18] Watanabe H，Tanabe N，Yagihara N，et al. Association between lipid profile and risk of atrial fibrillation [J]. Circ J，2011，75(12)：2767-2774.
[19] Díaz-Peromingo JA，Albán-Salgado A，García-Suárez F，et al. Lipoprotein(a) and lipid profile in patients with atrial fibrillation [J]. Med Sci Monit，2006，12(3)：CR122-CR125.
[20] Suzuki S. “Cholesterol paradox”in atrial fibrillation [J]. Circ J，2011，75(12)：2749-2750.
(收稿日期：2018-09-12 本文編辑：封 华), 百拇医药(邱娜 凌宏威 周冬梅)